Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study

Orna Diav-Citrin, Anna Otcheretianski-Volodarsky, Svetlana Shechtman, Asher Ornoy

פרסום מחקרי: פרסום בכתב עתמאמרביקורת עמיתים

94 ציטוטים ‏(Scopus)

תקציר

Objective: To evaluate pregnancy safety of anti-TNF-α medications. Design: Prospective, comparative, observational study done at the Israeli Teratology Information Service between 2002 and 2011. Results: 83 anti-TNF-α-exposed-pregnancies (97.6% in the first trimester, T1) were followed-up and compared with 86 disease-matched (DM) and 341 non-teratogenic-exposed (NTE) pregnancies. The anti-TNF-α group consisted of 35 infliximab-, 25 etanercept-, and 23 adalimumab-exposed pregnancies. The rate of major congenital anomalies did not significantly differ between the three groups [3/65 (4.6%) (anti-TNF-α, T1), 5/79 (6.3%) (DM), 8/336 (2.4%) (NTE)], even after excluding genetic or cytogenetic anomalies [3/65 (4.6%) (anti-TNF-α, T1), 4/79 (5.1%) (DM), 6/336 (1.8%) (NTE)]. There were no cases of VATER/VACTERL association. Conclusion: The present study suggests that anti-TNF-α treatment does not pose a major teratogenic risk in humans. This conclusion is based on relatively small numbers of exposed pregnancies and should be interpreted with caution. Larger studies are needed to establish anti-TNF-α pregnancy safety.

שפה מקוריתאנגלית
עמודים (מ-עד)78-84
מספר עמודים7
כתב עתReproductive Toxicology
כרך43
מזהי עצם דיגיטלי (DOIs)
סטטוס פרסוםפורסם - ינו׳ 2014
פורסם באופן חיצוניכן

טביעת אצבע

להלן מוצגים תחומי המחקר של הפרסום 'Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study'. יחד הם יוצרים טביעת אצבע ייחודית.

פורמט ציטוט ביבליוגרפי